Details of the Drug

General Information of Drug (ID: DM6AUFY)

Drug Name
Iloperidone
Synonyms
Fanapt; Fanapta; Fiapta; Zomaril; HP 873; Fanapt (TN); HP-873; ILO-522; Iloperidone [USAN:INN]; Fanapta, Zomaril, Iloperidone; Iloperidone (USAN/INN); 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone; 4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 426.5
Topological Polar Surface Area (xlogp) 4.1
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2-4 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Elimination
0.5% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 18 - 33 hours [5]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.804 micromolar/kg/day [6]
Vd
The volume of distribution (Vd) of drug is 1340-2800 L [7]
Water Solubility
The ability of drug to dissolve in water is measured as 0.03 mg/mL [4]
Chemical Identifiers
Formula
C24H27FN2O4
IUPAC Name
1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone
Canonical SMILES
CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC
InChI
InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3
InChIKey
XMXHEBAFVSFQEX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
71360
ChEBI ID
CHEBI:65173
CAS Number
133454-47-4
DrugBank ID
DB04946
TTD ID
D0M8VE
INTEDE ID
DR0856
ACDINA ID
D00323

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Antagonist [2], [8]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [2], [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [9]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.96E-01 -3.17E-03 -1.84E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Iloperidone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Iloperidone and Amisulpride. Schizophrenia [6A20] [61]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Iloperidone and Asenapine. Schizophrenia [6A20] [61]
Coadministration of a Drug Treating the Disease Different from Iloperidone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Iloperidone and Ivosidenib. Acute myeloid leukaemia [2A60] [61]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Iloperidone and Midostaurin. Acute myeloid leukaemia [2A60] [61]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Iloperidone and Arn-509. Acute myeloid leukaemia [2A60] [61]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Iloperidone and Gilteritinib. Acute myeloid leukaemia [2A60] [61]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Iloperidone and Oliceridine. Acute pain [MG31] [61]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Iloperidone and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [62]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Iloperidone and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [62]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Iloperidone and Ivabradine. Angina pectoris [BA40] [63]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Iloperidone and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [61]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Iloperidone and Levalbuterol. Asthma [CA23] [64]
Troleandomycin DMUZNIG Major Decreased metabolism of Iloperidone caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [65]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Iloperidone and Retigabine. Behcet disease [4A62] [61]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Iloperidone and Cariprazine. Bipolar disorder [6A60] [66]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Iloperidone and Eribulin. Breast cancer [2C60-2C6Y] [61]
Tucatinib DMBESUA Major Decreased metabolism of Iloperidone caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [65]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Iloperidone and Bosutinib. Breast cancer [2C60-2C6Y] [61]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Iloperidone and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [61]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Iloperidone and Olodaterol. Chronic obstructive pulmonary disease [CA22] [67]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Iloperidone and Vilanterol. Chronic obstructive pulmonary disease [CA22] [64]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Iloperidone and Indacaterol. Chronic obstructive pulmonary disease [CA22] [67]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Iloperidone and Pasireotide. Cushing syndrome [5A70] [61]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Iloperidone and Osilodrostat. Cushing syndrome [5A70] [61]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Iloperidone caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [68]
MK-8228 DMOB58Q Moderate Decreased metabolism of Iloperidone caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [69]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Iloperidone and OPC-34712. Depression [6A70-6A7Z] [66]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Iloperidone and Esketamine. Depression [6A70-6A7Z] [70]
Deutetrabenazine DMUPFLI Major Additive antidopaminergic effects by the combination of Iloperidone and Deutetrabenazine. Dystonic disorder [8A02] [71]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Iloperidone and Ingrezza. Dystonic disorder [8A02] [61]
Mirabegron DMS1GYT Moderate Decreased metabolism of Iloperidone caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [72]
Boceprevir DMBSHMF Major Decreased metabolism of Iloperidone caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [65]
Telaprevir DMMRV29 Major Decreased metabolism of Iloperidone caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [65]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Iloperidone and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [61]
Cobicistat DM6L4H2 Major Decreased metabolism of Iloperidone caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Iloperidone and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [61]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Iloperidone and Levamlodipine. Hypertension [BA00-BA04] [73]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Iloperidone and TAK-491. Hypertension [BA00-BA04] [73]
Givosiran DM5PFIJ Moderate Decreased metabolism of Iloperidone caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [74]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Iloperidone and Belladonna. Infectious gastroenteritis/colitis [1A40] [66]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Iloperidone caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [75]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Iloperidone and ITI-007. Insomnia [7A00-7A0Z] [66]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Iloperidone and Polyethylene glycol. Irritable bowel syndrome [DD91] [61]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Iloperidone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [63]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Iloperidone and Crizotinib. Lung cancer [2C25] [61]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Iloperidone and Ceritinib. Lung cancer [2C25] [61]
PF-06463922 DMKM7EW Moderate Increased metabolism of Iloperidone caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [76]
Dacomitinib DMOH8VY Major Decreased metabolism of Iloperidone caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [65]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Iloperidone and Osimertinib. Lung cancer [2C25] [61]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Iloperidone and Selpercatinib. Lung cancer [2C25] [61]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Iloperidone and Lumefantrine. Malaria [1F40-1F45] [70]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Iloperidone and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [61]
Idelalisib DM602WT Major Decreased metabolism of Iloperidone caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [65]
IPI-145 DMWA24P Moderate Decreased metabolism of Iloperidone caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [77]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Iloperidone and Vemurafenib. Melanoma [2C30] [61]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Iloperidone and LGX818. Melanoma [2C30] [61]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Iloperidone caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [63]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Iloperidone and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [78]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Iloperidone and Lasmiditan. Migraine [8A80] [79]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Iloperidone and Panobinostat. Multiple myeloma [2A83] [61]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Iloperidone and Siponimod. Multiple sclerosis [8A40] [70]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Iloperidone and Fingolimod. Multiple sclerosis [8A40] [61]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Iloperidone and Ozanimod. Multiple sclerosis [8A40] [61]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Iloperidone and Romidepsin. Mycosis fungoides [2B01] [61]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Iloperidone caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [63]
Rolapitant DM8XP26 Moderate Decreased metabolism of Iloperidone caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [80]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Iloperidone and Entrectinib. Non-small cell lung cancer [2C25] [61]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Iloperidone and Lofexidine. Opioid use disorder [6C43] [61]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Iloperidone and Rucaparib. Ovarian cancer [2C73] [61]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Iloperidone and Triclabendazole. Parasitic worm infestation [1F90] [61]
Opicapone DM1BKA6 Moderate Antagonize the effect of Iloperidone when combined with Opicapone. Parkinsonism [8A00] [81]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Iloperidone and Pimavanserin. Parkinsonism [8A00] [61]
Abametapir DM2RX0I Moderate Decreased metabolism of Iloperidone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [82]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Iloperidone and Methylscopolamine. Peptic ulcer [DA61] [66]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Iloperidone and Macimorelin. Pituitary gland disorder [5A60-5A61] [83]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Iloperidone and Lefamulin. Pneumonia [CA40] [84]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Iloperidone caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [65]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Iloperidone and Degarelix. Prostate cancer [2C82] [61]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Iloperidone and ABIRATERONE. Prostate cancer [2C82] [61]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Iloperidone and Enzalutamide. Prostate cancer [2C82] [61]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Iloperidone and Relugolix. Prostate cancer [2C82] [61]
Neupro DMHEAB1 Moderate Antagonize the effect of Iloperidone when combined with Neupro. Restless legs syndrome [7A80] [81]
Larotrectinib DM26CQR Moderate Decreased metabolism of Iloperidone caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [70]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Iloperidone and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [61]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Iloperidone and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [61]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Iloperidone and Pitolisant. Somnolence [MG42] [61]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Iloperidone and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [61]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Iloperidone caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [85]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Iloperidone and Lenvatinib. Thyroid cancer [2D10] [61]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Iloperidone and Cabozantinib. Thyroid cancer [2D10] [61]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Iloperidone and Acrivastine. Vasomotor/allergic rhinitis [CA08] [66]
⏷ Show the Full List of 89 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Crospovidone E00626 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
Water E00035 962 Solvent
⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Iloperidone 1 mg tablet 1 mg Oral Tablet Oral
Iloperidone 10 mg tablet 10 mg Oral Tablet Oral
Iloperidone 12 mg tablet 12 mg Oral Tablet Oral
Iloperidone 2 mg tablet 2 mg Oral Tablet Oral
Iloperidone 4 mg tablet 4 mg Oral Tablet Oral
Iloperidone 6 mg tablet 6 mg Oral Tablet Oral
Iloperidone 8 mg tablet 8 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 87).
2 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
9 Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. Acta Pharmacol Sin. 2016 Nov;37(11):1499-1508.
10 Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
21 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
22 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
23 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
24 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
25 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
26 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
27 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
28 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
29 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
30 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
31 Drug Interactions Flockhart Table
32 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
33 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
34 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
35 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
36 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
37 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
38 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
39 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
40 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
41 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
42 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
43 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
44 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
45 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
46 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
47 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
48 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
49 Clinical pipeline report, company report or official report of Lundbeck.
50 Central serotonin receptors as targets for drug research. J Med Chem. 1987 Jan;30(1):1-12.
51 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
52 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
53 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
54 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
55 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
56 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
57 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
58 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
59 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
60 Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8.
61 Canadian Pharmacists Association.
62 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
63 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
64 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
65 Product Information. Fanapt (iloperidone). Vanda Pharmaceuticals Inc, Rockville, MD.
66 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
67 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
68 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
69 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
70 Cerner Multum, Inc. "Australian Product Information.".
71 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
72 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
73 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
74 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
75 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
76 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
77 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
78 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
79 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
80 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
81 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
82 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
83 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
84 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
85 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.